Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy 09/02/2020 Medications South San Francisco, CA — January 22, 2020 — Genentech, Read more